MANILA, Philippines — Two leaders of the House of Representatives are pushing for an inquiry into the Department of Health and the Food and Drug Administration’s policies and guidelines for the registration, utilization, manufacture, distribution, and sale of drug products for COVID-19.
Under House Resolution No. 1711, filed by House Speaker Lord Allan Velasco and Deputy Speaker Bernadette Herrera-Dy, the House committee on good government and public accountability is urged to conduct the said inquiry, particularly on the “policies and guidelines which appear to be detrimental to the public interest.”
Specifically, the lawmakers want to look at FDA Circular No. 2020…
Keep on reading: House probe urged on ‘detrimental’ DOH, FDA rules for COVID drug registration